Clinical trials: Rituximab, completed
Opsoclonus-myoclonus Syndrome
Study of Cytokines in Children With Opsoclonus-Myoclonus Syndrome
The purpose of this study is to determine if cytokines, inflammatory mediators, are increased in spinal fluid and blood, correlate with disease activity, and could serve as biomarkers or therapeutic targets in children with…
- Trial name
- OMS (NCT00806182)
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- National Pediatric Neuroinflammation Organization, Inc.
Membranous Nephropathy, Membranous Nephropathy - PLA2R Induced
Analysis of T- and B-Cell Subpopulations in Membranous Nephropathy
The aim of this observational study is to provide analysis of T and B lymphocyte subgroups in peripheral blood samples of patients with primary membranous nephropathy (MN).
- Conditions
- Membranous Nephropathy, Membranous Nephropathy - PLA2R Induced, Membranous Nephropathy - THSD7A Induced
- Trial name
- NCT05894512
- Where
- Turkey (Türkiye)
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Istanbul University
Follicular Non-Hodgkin's Lymphoma
Study to Evaluate the Efficacy of Response-adapted Strategy in Follicular Lymphoma
Recently, the availability of R has substantially changed therapeutic approach to FL patients, since its combination with chemotherapy has improved response rates, progression free survival (PFS) and overall survival (OS).
- Trial name
- NCT02063685
- Testing
- R-CHOP or R-bendamustine, Observation, Maintenance weekly x4
- Where
- 48 sites in Italy
- Volunteers
- 807 people, healthy volunteers welcome
- Sponsor
- Fondazione Italiana Linfomi - ETS
Waldenstrom's Macroglobulinemia
Fase II Study With BRB for Non-Hodgkin Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia's
This is a prospective, multicenter phase II trial designed to determine efficacy and safety of Bortezomib plus Rituximab plus Bendamustine in patients with relapsed/refractory Waldenstrom's Macroglobulinemia.
- Trial name
- FIL_BRB (NCT02371148)
- Testing
- Bortezomib-Rituximab-Bendamustine
- Where
- 23 sites in Italy
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Fondazione Italiana Linfomi - ETS
Lymphoma
Avastin Plus Rituximab for Patients With B-Cell Non-Hodgkin's Lymphoma
Phase II Study of Avastin Plus Rituximab for Patients with Relapsed and Chemotherapy - or Rituxan Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma.
- Trial name
- NCT00081861
- Testing
- Avastin, Rituximab
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Lymphoma
Rituximab Combined With ESHAP in Patients With Relapse or Refractory Diffuse Large B Cell Lymphoma (DLBCL)
The purpose of this study is to evaluate the efficacy and toxicity of Rituximab combined with ESHAP (etoposide, methylprednisolone, cytarabine, and cisplatin) in the patients with diffuse large B cell lymphoma (DLBCL).
- Trial name
- NCT00568815
- Testing
- Rituximab combined with ESHAP
- Where
- China
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Fudan University
Nephrotic Syndrome
B Cells in Idiopathic Nephrotic Syndrome
The main aim of the present study is to determine whether reconstitution of different B-cell subpopulations can predict relapse after treatment with B-cell depleting antibodies in adult with NS, and whether specific B- or T-cell…
- Trial name
- BLADE (NCT05712369)
- Testing
- Blood sampling
- Where
- Italy
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Mario Negri Institute for Pharmacological Research
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
The Evaluation of Efficacy and Safety of Rituximab in Refractory CIDP Patients With IgG4 Autoantibodies
To evaluate the efficacy and safety of rituximab (genetical recombination) intravenously administered to CIDP patients with positive or negative IgG4 autoantibody.
- Trial name
- RECIPE (NCT03864185)
- Testing
- Rituximab (genetical recombination)
- Where
- 4 sites in Japan
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Nagoya University
Multiple Sclerosis
Safety of Switching From Rituximab to Ocrelizumab in MS Patients
This is a prospective between and within group observational study to determine differences in tolerability, immunogenicity and safety related outcomes for 100 multiple sclerosis (MS) patients who have been administered at least…
- Trial name
- NCT02980042
- Testing
- Ocrelizumab, Rituximab
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Hematopoietic Cell Transplantation Recipient, Refractory B-Cell Non-Hodgkin Lymphoma
Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma
This phase I/II trial studies the side effects and best dose of gemcitabine hydrochloride, clofarabine, and busulfan before donor stem cell transplant and to see how well it works in treating patients with B-cell or T-cell…
- Conditions
- Hematopoietic Cell Transplantation Recipient, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma
- Trial name
- NCT01701986
- Testing
- Allogeneic Bone Marrow Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, Anti-Thymocyte Globulin
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Primary Sjögren's Syndrome, Xerostomia
Effect of B-cell Depletion in Patients With Primary Sjögren's Syndrome
The primary purpose of the study is to determine whether B-cell depletion with Rituximab has an effect on the oral, ocular and general disease manifestations in patients with primary Sjögren´s syndrome, that is, an effect on the…
- Conditions
- Primary Sjögren's Syndrome, Xerostomia, Hyposalivation, Keratoconjunctivitis Sicca
- Trial name
- NCT00426543
- Testing
- MabThera (rituximab), Rituximab, Mabthera
- Where
- Denmark
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- University of Copenhagen
EBV-induced Lymphomas, EBV-associated Malignancies
Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies
This is a Phase II trial to evaluate the efficacy and safety of human leukocyte antigen (HLA) partially-matched third-party allogeneic Epstein-Barr virus cytotoxic T lymphocytes (EBV-CTLs) for the treatment of EBV-induced…
- Conditions
- EBV-induced Lymphomas, EBV-associated Malignancies, Transplant Patients With EBV Viremia at High Risk for Developing a Recurrent EBV Lymphoma
- Trial name
- NCT01498484
- Testing
- EBV-specific T cells (EBV-CTLs)
- Where
- United States
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Atara Biotherapeutics
Lymphoma, Follicular
Follow-up Trial of Rituximab Interferon Transplant Trial: Study Drug-Rituximab and Alpha Interferon
A previous phase II trial entitled Treatment of Follicular non-Hodgkin's Lymphoma with High Dose Therapy and Stem Cell Support Followed by Consolidative Immunotherapy with Rituximab and Alpha Interferon was conducted at the…
- Trial name
- NCT03087929
- Testing
- Follow up
- Where
- Canada
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Sunnybrook Health Sciences Centre
Non-Hodgkin Lymphoma (NHL)
Response to Influenza Vaccination in Lymphoma Patients Treated With Rituximab
The purpose of this study is to compare the number of responders to vaccination with the influenza virus vaccine at different time points after last dose of rituximab in patients with lymphoma.
- Trial name
- Rituxivac (NCT01707628)
- Testing
- influenza vaccination with influenza vaccine
- Where
- 7 sites in Netherlands
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- St. Antonius Hospital
Cognitive Impairment, Autoimmune Encephalitis
To Explore Cognitive Neural Mechanism of Autoimmune Encephalitis by Using Neuropsychological Tests and Multi-modal MRI
Most of patients with autoimmune encephalitis are left with permanent cognitive deficits of varying severity. The patients' life and career would be affected definitely by cognitive deficits.
- Trial name
- NCT03530462
- Testing
- rituximab, cyclophosphamide, Steroids
- Where
- China
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Zhejiang University
Lymphoma, Mantle-Cell
Study Of Yttrium-ibritumomab (Zevalin) For the Treatment Of Patients With Relapsed And Refractory Mantle Cell Lymphoma
Study of Yttrium-ibritumomab (Zevalin) For the treatment of Patients with Relapsed \& Refractory Mantle Cell Lymphoma
- Trial name
- NCT00038623
- Testing
- Yttrium-ibritumomab (Zevalin), Rituximab
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Systemic Vasculitis
Acquired Immunodeficiency in ANCA Associated Vasculitis
This study will address the following hypothesis: Rituximab therapy leads to an acquired immune deficiency, as demonstrated by impaired vaccine responses, in AAV patients. Aims: 1.
- Trial name
- ACQUIVAS (NCT03514979)
- Testing
- Pneumococcal Polysaccharide Conjugate vaccination and Pneumococcal Polysaccharide Vaccination
- Where
- United Kingdom
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Multiple Myeloma, Non-Hodgkin Lymphoma
Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL
This is a phase I trial with pilot expansion of HLA-haploidentical or HLA-mismatched related donor nicotinamide expanded-natural killer (NAM-NK) cell based therapy for patients with relapsed or refractory multiple myeloma (MM) or…
- Conditions
- Multiple Myeloma, Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Mantle-Cell Lymphoma
- Trial name
- NCT03019666
- Testing
- Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Masonic Cancer Center, University of Minnesota